Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure
Background: Endothelial progenitor cells (EPCs) are known to play a significant role in reendothelialization and vascular repair. Recently, a mineralocorticoid receptor was demonstrated to be expressed by EPCs. The study aimed to evaluate a potential influence of eplerenone treatment on the total nu...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2012-09-01
|
| Series: | Journal of the Renin-Angiotensin-Aldosterone System |
| Online Access: | https://doi.org/10.1177/1470320312447650 |
| _version_ | 1797284149106573312 |
|---|---|
| author | Christian Jung Anna Florvaag Volker Oberle Michael Fritzenwanger Daniel Kretschmar Friedhelm Kuethe Stefan Betge Bjoern Goebel Marcus Franz Dagmar Barz Markus Ferrari Hans R Figulla |
| author_facet | Christian Jung Anna Florvaag Volker Oberle Michael Fritzenwanger Daniel Kretschmar Friedhelm Kuethe Stefan Betge Bjoern Goebel Marcus Franz Dagmar Barz Markus Ferrari Hans R Figulla |
| author_sort | Christian Jung |
| collection | DOAJ |
| description | Background: Endothelial progenitor cells (EPCs) are known to play a significant role in reendothelialization and vascular repair. Recently, a mineralocorticoid receptor was demonstrated to be expressed by EPCs. The study aimed to evaluate a potential influence of eplerenone treatment on the total number of EPCs in patients with chronic heart failure. Methods: Eighty-seven male patients with chronic heart failure were included (age: 23–83 years; body mass index 29.1 ± 5.1 kg/m 2 ; New York Heart failure classification (NYHA) I: 29 patients, NYHA II: 32 patients, NYHA III: 26 patients). Numbers of circulating EPCs were quantified immediately using flow cytometry. Twenty-eight patients received therapy with eplerenone. Patients were further characterized by echocardiography, spirometry and laboratory markers. Results: Patients with ongoing eplerenone administration showed higher levels of circulating cells expressing CD34+ ( p <0.05) and CD34+KDR+ ( p <0.05) and CD34+CD133+KDR+ cells ( p <0.05). The effects of eplerenone treatment could be shown to be independent of NYHA status, genesis of the underlying cardiovascular morbidity, left ventricular function and co-medication. Conclusion: Patients with chronic heart failure treated with eplerenone show higher numbers of EPCs. The clinical benefit for treatment with eplerenone has been demonstrated even for patients with mild heart failure and might be partially mediated by EPCs. |
| first_indexed | 2024-03-07T17:44:50Z |
| format | Article |
| id | doaj.art-5c00535d21c44308b9e8af5399db09db |
| institution | Directory Open Access Journal |
| issn | 1470-3203 1752-8976 |
| language | English |
| last_indexed | 2024-03-07T17:44:50Z |
| publishDate | 2012-09-01 |
| publisher | SAGE Publications |
| record_format | Article |
| series | Journal of the Renin-Angiotensin-Aldosterone System |
| spelling | doaj.art-5c00535d21c44308b9e8af5399db09db2024-03-02T15:18:54ZengSAGE PublicationsJournal of the Renin-Angiotensin-Aldosterone System1470-32031752-89762012-09-011310.1177/1470320312447650Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failureChristian Jung0Anna Florvaag1Volker Oberle2Michael Fritzenwanger3Daniel Kretschmar4Friedhelm Kuethe5Stefan Betge6Bjoern Goebel7Marcus Franz8Dagmar Barz9Markus Ferrari10Hans R Figulla11First Department of Medicine, Friedrich-Schiller-University Jena, GermanyFirst Department of Medicine, Friedrich-Schiller-University Jena, GermanyDivision of Cardiology, Institute for Transfusion Medicine, Friedrich-Schiller-University Jena, GermanyFirst Department of Medicine, Friedrich-Schiller-University Jena, GermanyFirst Department of Medicine, Friedrich-Schiller-University Jena, GermanyFirst Department of Medicine, Friedrich-Schiller-University Jena, GermanyFirst Department of Medicine, Friedrich-Schiller-University Jena, GermanyFirst Department of Medicine, Friedrich-Schiller-University Jena, GermanyFirst Department of Medicine, Friedrich-Schiller-University Jena, GermanyDivision of Cardiology, Institute for Transfusion Medicine, Friedrich-Schiller-University Jena, GermanyFirst Department of Medicine, Friedrich-Schiller-University Jena, GermanyFirst Department of Medicine, Friedrich-Schiller-University Jena, GermanyBackground: Endothelial progenitor cells (EPCs) are known to play a significant role in reendothelialization and vascular repair. Recently, a mineralocorticoid receptor was demonstrated to be expressed by EPCs. The study aimed to evaluate a potential influence of eplerenone treatment on the total number of EPCs in patients with chronic heart failure. Methods: Eighty-seven male patients with chronic heart failure were included (age: 23–83 years; body mass index 29.1 ± 5.1 kg/m 2 ; New York Heart failure classification (NYHA) I: 29 patients, NYHA II: 32 patients, NYHA III: 26 patients). Numbers of circulating EPCs were quantified immediately using flow cytometry. Twenty-eight patients received therapy with eplerenone. Patients were further characterized by echocardiography, spirometry and laboratory markers. Results: Patients with ongoing eplerenone administration showed higher levels of circulating cells expressing CD34+ ( p <0.05) and CD34+KDR+ ( p <0.05) and CD34+CD133+KDR+ cells ( p <0.05). The effects of eplerenone treatment could be shown to be independent of NYHA status, genesis of the underlying cardiovascular morbidity, left ventricular function and co-medication. Conclusion: Patients with chronic heart failure treated with eplerenone show higher numbers of EPCs. The clinical benefit for treatment with eplerenone has been demonstrated even for patients with mild heart failure and might be partially mediated by EPCs.https://doi.org/10.1177/1470320312447650 |
| spellingShingle | Christian Jung Anna Florvaag Volker Oberle Michael Fritzenwanger Daniel Kretschmar Friedhelm Kuethe Stefan Betge Bjoern Goebel Marcus Franz Dagmar Barz Markus Ferrari Hans R Figulla Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure Journal of the Renin-Angiotensin-Aldosterone System |
| title | Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure |
| title_full | Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure |
| title_fullStr | Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure |
| title_full_unstemmed | Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure |
| title_short | Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure |
| title_sort | positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure |
| url | https://doi.org/10.1177/1470320312447650 |
| work_keys_str_mv | AT christianjung positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT annaflorvaag positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT volkeroberle positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT michaelfritzenwanger positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT danielkretschmar positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT friedhelmkuethe positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT stefanbetge positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT bjoerngoebel positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT marcusfranz positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT dagmarbarz positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT markusferrari positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure AT hansrfigulla positiveeffectofeplerenonetreatmentonendothelialprogenitorcellsinpatientswithchronicheartfailure |